Determining Treatment for Older Patients with High-Risk MDS and AML: Which Factors Predict Optimal Quality of Life?

被引：0
|
作者：
Tinsley-Vance, Sara M. [1 ]
Small, Brent J. [2 ]
McMillan, Susan C. [3 ]
Komrokji, Rami S. [4 ]
Lancet, Jeffrey E. [4 ]
机构：
[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol, Tampa, FL 33612 USA
[2] Univ S Florida, Dept Aging Studies, Tampa, FL 33620 USA
[3] Univ S Florida, Coll Nursing, Tampa, FL 33620 USA
[4] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL 33612 USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS
    Ossenkoppele, G. J.
    Breems, D. A.
    Stuessi, G.
    Van Norden, Y.
    Bargetzi, M.
    Biemond, B. J.
    A von dem Borne, P.
    Chalandon, Y.
    Cloos, J.
    Deeren, D.
    Fehr, M.
    Gjertsen, B.
    Graux, C.
    Huls, G.
    Janssen, J. J. J. W.
    Jaspers, A.
    Jongen-Lavrencic, M.
    De Jongh, E.
    Klein, S. K.
    Van der Klift, M.
    Van Marwijk Kooy, M.
    Maertens, J.
    Micheaux, L.
    Van der Poel, M. W. M.
    Van Rhenen, A.
    Tick, L.
    Valk, P.
    Vekemans, M. C.
    Van der Velden, W. J. F. M.
    De Weerdt, O.
    Pabst, T.
    Manz, M.
    Lowenberg, B.
    Havelange
    Vekemans, M-C
    Moors, I.
    Van Obberg, F.
    Maertens, J. A.
    Hodossy, B.
    Vansteenweghen, S.
    Lammertijn, L.
    Sonet, A.
    Triffet, A.
    Gjertsen, B. T.
    Passweg, J.
    Heim, D.
    Giovanni, San
    Stuessi, Georg
    Betticher, D.
    Chalandon, Y.
    [J]. LEUKEMIA, 2020, 34 (07) : 1751 - 1759
  • [2] Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS
    G. J. Ossenkoppele
    D. A. Breems
    G. Stuessi
    Y. van Norden
    M. Bargetzi
    B. J. Biemond
    P. A von dem Borne
    Y. Chalandon
    J. Cloos
    D. Deeren
    M. Fehr
    B. Gjertsen
    C. Graux
    G. Huls
    J. J. J. W. Janssen
    A. Jaspers
    M. Jongen-Lavrencic
    E. de Jongh
    S. K. Klein
    M. van der Klift
    M. van Marwijk Kooy
    J. Maertens
    L. Michaux
    M. W. M. van der Poel
    A. van Rhenen
    L. Tick
    P. Valk
    M. C. Vekemans
    W. J. F. M. van der Velden
    O. de Weerdt
    T. Pabst
    M. Manz
    B. Löwenberg
    [J]. Leukemia, 2020, 34 : 1751 - 1759
  • [3] Identifying Salient Quality of Life Domains in Patients Living with High-Risk MDS and AML
    Messina, Anthony J.
    Figueiredo, Sabrina
    Powers, John H., III
    Corcoran, Mary A.
    [J]. BLOOD, 2021, 138
  • [4] Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS
    G. J. Ossenkoppele
    D. A. Breems
    G. Stuessi
    Y. van Norden
    M. Bargetzi
    B. J. Biemond
    P. A von dem Borne
    Y. Chalandon
    J. Cloos
    D. Deeren
    M. Fehr
    B. Gjertsen
    C. Graux
    G. Huls
    J. J. J. W. Janssen
    A. Jaspers
    M. Jongen-Lavrencic
    E. de Jongh
    S. K. Klein
    M. van der Klift
    M. van Marwijk Kooy
    J. Maertens
    L. Michaux
    M. W. M. van der Poel
    A. van Rhenen
    L. Tick
    P. Valk
    M. C. Vekemans
    W. J. F. M. van der Velden
    O. de Weerdt
    T. Pabst
    M. Manz
    B. Löwenberg
    [J]. Leukemia, 2020, 34 : 2820 - 2820
  • [5] Geriatric assessment:: a prospective study in older patients with AML and high-risk MDS
    Deschler, B.
    Ihorst, G.
    Kuhn, M.
    Rueter, B.
    Luebbert, M.
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2006, 60 : S26 - S27
  • [6] Copy number profiles of high-risk MDS and AML patients
    Ganster, C.
    Braulke, F.
    Shirneshan, K.
    Schanz, J.
    Neesen, J.
    Salinas-Riester, G.
    Platzbecker, U.
    Haase, D.
    [J]. ONKOLOGIE, 2013, 36 : 239 - 240
  • [7] Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (vol 66, pg 813, 2020)
    Ossenkoppele, G. J.
    Breems, D. A.
    Stuessi, G.
    van Norden, Y.
    Bargetzi, M.
    Biemond, B. J.
    von dem Borne, P.
    Chalandon, Y.
    Cloos, J.
    Deeren, D.
    Fehr, M.
    Gjertsen, B.
    Graux, C.
    Huls, G.
    Janssen, J. J. J. W.
    Jaspers, A.
    Jongen-Lavrencic, M.
    de Jongh, E.
    Klein, S. K.
    van der Klift, M.
    van Marwijk Kooy, M.
    Maertens, J.
    Michaux, L.
    van der Poel, M. W. M.
    van Rhenen, A.
    Tick, L.
    Valk, P.
    Vekemans, M. C.
    van der Velden, W. J. F. M.
    de Weerdt, O.
    Pabst, T.
    Manz, M.
    Lowenberg, B.
    [J]. LEUKEMIA, 2020, 34 (10) : 2820 - 2820
  • [8] A pilot study of bendamustine in elderly patients with high-risk MDS and AML
    Strupp, C.
    Knipp, S.
    Hartmann, J.
    Gattermann, N.
    Haas, R.
    Germing, U.
    [J]. LEUKEMIA & LYMPHOMA, 2007, 48 (06) : 1161 - 1166
  • [9] An inexpensive way to treat elderly patients with high-risk MDS or AML
    Kuendgen, Andrea
    [J]. LEUKEMIA RESEARCH, 2011, 35 (08) : 985 - 986
  • [10] A Phase I/II Study Of Cytarabine Or Azacitidine In Combination With Tosedostat In Older Patients With AML Or High-Risk MDS
    DiNardo, Courtney D.
    Kantarjian, Hagop M.
    Ravandi, Farhad
    Konopleva, Marina
    Kadia, Tapan M.
    Borthakur, Gautam
    Daver, Naval G.
    Durand, Mends
    Rivera, Silvia
    Quintas-Cardama, Alfonso
    Garcia-Manero, Guillermo
    Cortes, Jorge E.
    [J]. BLOOD, 2013, 122 (21)
12345